Seattle Genetics Mounts 3rd Bid To Defeat Stock Fraud Suit
Cancer-drug maker Seattle Genetics Inc. on Friday asked a Washington federal court for a third time to dismiss a proposed securities fraud class action against it, saying the latest complaint still...To view the full article, register now.
Already a subscriber? Click here to view full article